What is the significance and recommended management of abnormal Pap smear results such as ASC-US (Atypical Squamous Cells of Undetermined Significance), LSIL (Low‑grade Squamous Intraepithelial Lesion), ASC-H (Atypical Squamous Cells – cannot exclude HSIL), HSIL (High‑grade Squamous Intraepithelial Lesion), AGC (Atypical Glandular Cells), and carcinoma in women aged 21‑65?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 9, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Abnormal Pap Smear Results: Significance and Management

ASC-US (Atypical Squamous Cells of Undetermined Significance)

Reflex HPV DNA testing is the preferred management strategy for ASC-US, with immediate colposcopy for HPV-positive patients and repeat co-testing in 1 year for HPV-negative patients. 1, 2

Clinical Significance

  • ASC-US represents approximately 4% of all cervical cytology smears and carries a 9.7% risk of underlying high-grade cervical disease (CIN 2 or worse) 1, 2
  • Despite the benign-sounding name, more than 40% of high-grade lesions (CIN II/III or cancer) can be discovered within atypical cytology categories 3

Management Algorithm

  • HPV-positive ASC-US: Proceed directly to colposcopy, as this carries an 18% 5-year risk of histologic HSIL and cancer 1, 2
  • HPV-negative ASC-US: Repeat co-testing (Pap plus HPV) in 1 year; if both remain negative, return to routine age-appropriate screening 1, 2
  • Reflex HPV testing identifies 92.4% of women with CIN III while reducing unnecessary colposcopy referrals to 55.6% compared to 67.1% with repeat cytology alone 2

Critical Pitfalls

  • Never delay follow-up beyond 180 days, as delays are associated with increased risk of progression and delayed cancer diagnosis 2
  • Do not exit screening at age 65 with a recent ASC-US result, even if HPV-negative, as this is insufficient for safe screening cessation 4

LSIL (Low-Grade Squamous Intraepithelial Lesion)

All women with LSIL should be referred for colposcopy, as 80-85% are high-risk HPV positive. 3

Clinical Significance

  • LSIL is almost synonymous with HPV infection, with the vast majority testing positive for high-risk HPV types 3
  • LSIL represents a lower cancer risk than higher-grade lesions but still requires evaluation to exclude concurrent high-grade disease 3

Management Algorithm

  • Immediate colposcopy with directed biopsy is recommended for all women with LSIL 3
  • If colposcopy shows only CIN 1 and original cytology was LSIL (not HSIL), follow-up with cytology at 6 and 12 months or HPV DNA testing at 12 months is acceptable 3
  • If CIN 1 persists for at least 2 years, continued observation or treatment are both options 3

ASC-H (Atypical Squamous Cells – Cannot Exclude HSIL)

Women with ASC-H require immediate colposcopy regardless of HPV status, as 40-48% have high-grade squamous intraepithelial lesions on biopsy. 2, 5

Clinical Significance

  • ASC-H is an uncommon interpretation (less common than ASC-US) but carries significantly higher risk 5
  • The positive predictive value for CIN 2 or worse ranges from 27.2% to 40.5%, with most lesions being CIN 3 5
  • Oncogenic HPV DNA is detected in 69.8-85.6% of ASC-H cases 5

Management Algorithm

  • Never use HPV testing to triage ASC-H – these patients require immediate colposcopy with directed biopsy 2
  • The high positive predictive value for high-grade lesions justifies immediate colposcopic evaluation without preliminary HPV testing 5

HSIL (High-Grade Squamous Intraepithelial Lesion)

HSIL management is the least controversial: immediate referral for colposcopy with directed biopsy and generally treatment. 3

Clinical Significance

  • CIN 3 (the histologic correlate of HSIL) is considered a true cancer precursor, with approximately 12% progressing to invasive cancer if untreated 3
  • About 33% of CIN 3 lesions regress spontaneously, while the remainder persist as CIN 3 3

Management Algorithm

  • For women with CIN 2,3 and satisfactory colposcopy, ablation or diagnostic excision is acceptable 3
  • Observation is unacceptable for non-pregnant, non-adolescent women with CIN 2,3 3
  • If colposcopy is unsatisfactory or if CIN 2,3 recurs, diagnostic excision is mandatory 3

Post-Treatment Surveillance

  • HPV testing has the highest negative predictive value (98%) for detecting residual or recurrent disease after treatment, superior to negative resection margins (91%) or cervical cytology alone (93%) 3
  • Women who remain HPV-positive after treatment for CIN 2,3 are at significantly increased risk of recurrent or residual CIN 3

AGC (Atypical Glandular Cells)

All women with AGC require immediate colposcopy with endocervical sampling and HPV DNA testing, as up to 38% have significant squamous or glandular lesions. 3

Clinical Significance

  • AGC represents only 0.2% of cytologic smears but carries disproportionately high risk 3
  • Although benign lesions are most common, CIN is the most frequent pathology, especially in women younger than 35 years 3
  • HPV positivity in AGC has a high positive predictive value, with 20% of women having CIN 3 or cancer on biopsy 3

Management Algorithm

  • Initial evaluation includes: colposcopy with endocervical sampling AND HPV DNA testing for all AGC subcategories 3
  • Endometrial sampling is also required for women 35 years and older, or younger women with risk factors for endometrial cancer 3
  • Reflex HPV testing or repeat cytology alone is unacceptable as initial triage for AGC-NOS, AGC-favor neoplasia, or AIS 3

Follow-Up After Initial Negative Evaluation

  • If HPV-positive: repeat cytology and HPV testing at 6 months 3
  • If HPV-negative: repeat cytology and HPV testing at 12 months 3
  • If both HPV and cytology are negative on re-evaluation, annual cytologic testing may resume 3
  • If AGC-favor neoplasia or AIS: excisional procedure may be required despite initial negative testing 3

Carcinoma

Any cytology showing invasive carcinoma requires immediate referral to gynecologic oncology for comprehensive evaluation and staging. 3

Clinical Significance

  • Invasive carcinoma on cytology represents the highest-risk category and requires urgent subspecialty management 3
  • Mean age of patients with invasive carcinoma is approximately 57 years 6

Special Population Considerations

HIV-Infected Women

  • All HIV-infected women with ASC-US or ASC-H should undergo immediate colposcopy, regardless of HPV status 2
  • HIV-infected women have 10-11 times higher rates of abnormal cervical cytology and 60% progression to SIL compared to 25% in HIV-negative women 4, 2
  • More frequent screening is required: twice during the first year after HIV diagnosis, then annually if normal 2

Women Aged 21-24 Years

  • Conservative management is recommended due to high rates of HPV infection and spontaneous regression in this age group 3, 2
  • Co-testing is not recommended for screening in women aged 21-29 years 3

Pregnant Women

  • Colposcopic biopsy should be performed only for lesions suspicious for cancer or CIN 2/3 3, 2
  • Avoid unnecessary biopsies of low-grade appearing lesions during pregnancy 2

Postmenopausal Women

  • Endometrial assessment is recommended for postmenopausal women with benign endometrial cells, as 7% will have significant endometrial pathology 3
  • Women over 60 years with HPV-positive ASC-US may have higher risk for cervical cancer during follow-up than younger women 4

References

Guideline

ASC-US Management Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Atypical Squamous Cells on Pap Smear

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of ASC-US with Atrophic Changes

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the difference between Atypical Squamous Cells of Undetermined Significance (ASCUS), High-grade Squamous Intraepithelial Lesion (HSIL), and Low-grade Squamous Intraepithelial Lesion (LSIL)?
Can a 99213 (Current Procedural Terminology) code be used for a routine Pap smear visit for a female patient of reproductive age with no previous history of cervical cancer or abnormal Pap smear results?
What is the CPT (Current Procedural Terminology) code for a routine pap smear test in a female patient between 21 and 65 years old with no history of cervical cancer or abnormal pap smear results?
What are common abbreviations in Obstetrics and Gynecology (OB-GYN), including High-grade Squamous Intraepithelial Lesion (HSIL) and Low-grade Squamous Intraepithelial Lesion (LSIL)?
What is the recommended cervical cancer screening schedule for a [AGE]-year-old woman with a last normal Pap (Papanicolau) smear in [YEAR]?
What are the TORCH infections (Toxoplasma gondii, Other infections such as syphilis, varicella‑zoster virus, parvovirus B19, HIV, Rubella virus, Cytomegalovirus, and Herpes simplex virus) and what are the recommended screening and management strategies for each in pregnant patients?
For a prostate cancer patient with a pathological hip fracture treated by intramedullary nail fixation, how many weeks should we wait before initiating adjuvant radiotherapy?
How should I evaluate and manage a hypertensive patient on spironolactone, furosemide, amlodipine, and clopidogrel who now presents with unsteady gait?
Is a thrombus in the left gastrocnemius vein considered a deep vein thrombosis?
When should asymptomatic bacteriuria (≥10⁵ CFU/mL) be treated in healthy non‑pregnant adults, pregnant women, patients undergoing urologic procedures, and immunocompromised or catheterized patients?
What is the recommended ritonavir (pharmacokinetic booster) dose, hepatic dose adjustments, major CYP3A drug interactions, monitoring requirements, and alternative boosters?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.